Wize Pharma Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Wize Pharma Inc.
Dermatology-focused regenerative medicine firm Fibrocell has been reviewing strategic opportunities for more than a year; April’s FCX-007 license deal with Castle Creek results in buyout.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced May-June 2015.
Sigma-Tau sold Baxter its leukemia drug Oncaspar for $900 million; CVS boosted its retail pharmacy business with Omnicare purchase. There was a strong showing of PIPEs in the $3 billion in biopharma financing.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2015.
- Other Names / Subsidiaries
- OphthaliX, Inc.
- Ocuwize LTD
- Wize Israel
- Wize Pharma Ltd.